News

Possible Parkinson’s Stem Cell Treatment in San Diego, $6.5 Million and Loads of Media Coverage

by

A San Diego firm that has $22 million worth of financial roots in the California stem cell agency this month snagged a bonus — a ton of favorable attention for its efforts to treat Parkinson’s disease.  The fledgling business is Aspen Neuroscience, Inc., which was co-founded by Jeanne Loring, professor emeritus at the Scripps Research … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Pioneering cell therapy for Parkinson’s disease gains funding boost

by

An autologous stem cell therapy for Parkinson’s disease (PD), with a potential to alter disease progression, received a boost when the programme received a seed funding totalling $6.5m from a group of venture capitalist firms. The funding is likely to help the company in advancing the programme to different stages of clinical development. 

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

How Research in Space Can Launch Girls’ Ideas

by

What if… …examining barley seeds in microgravity could help us grow food in space and improve crop growth back on the ground? …sending mice into orbit could teach us how to prevent human bone and muscle loss on Earth? …researching how cells grow in spaceflight could help patients on Earth living with Parkinson’s disease and … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Jeanne Loring named ‘Stem Cell Pioneer of the Year’ in inaugural Xconomy Awards

by

Genomics researcher Jeanne Loring, PhD, professor emeritus at Scripps Research and founding director of the institute’s Center for Regenerative Medicine, was honored as “Stem Cell Pioneer of the Year” at the Xconomy Awards San Diego’s gala. The award is an acknowledgement of Loring’s groundbreaking work not only in academia but also as co-founder and chief … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

The first 3D models of Parkinson’s, MS are headed into space

by

A group of brain organoids are set to blast off to the International Space Station (ISS) Wednesday, the first to model Parkinson’s disease and multiple sclerosis (MS) in microgravity. A team of researchers from across the country believes the models could shed light on how brain cells behave in these diseases and uncover new approaches … Read more

Aspen Neuroscience does not make determination on patient eligibility for clinical trials and all trial related enrollment and eligibility decisions are made by clinical trial sites under the direction of a Principal Investigator. ANPD001 is investigational and is not yet approved by the FDA. At this time, Aspen Neuroscience does not offer or participate in compassionate use or expanded access programs for ANPD001.

Aspen Neuroscience Logo

Aspen Neuroscience leverages stem cell biology and genomics to provide the world’s first autologous induced pluripotent stem cell (iPSC)-derived neuron replacement therapy for Parkinson's disease.

Contact

10835 Road to the Cure
Ste. 100
San Diego, CA 92121

© 2025 Aspen Neuroscience - All Rights Reserved